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Abstract: We compared fluor-18 choline positron emission tomography/computed tomography
(PET/CT) and axial skeleton magnetic resonance imaging (MRI) prospectively obtained for the
detection of bone metastases in non-castrated patients with biochemically recurrent prostate cancer
following primary treatment. PET/CT was performed 45 min post-injection of 3–4 MBq/kg F-18
methyl choline. MRI included T1- and fluid sensitive T2-weighted images of the spine and pelvis.
Readers were initially blinded from other results and all scans underwent independent double
reading. The best valuable comparator (BVC) defined the metastatic status. On the basis of the
BVC, 15 out of 64 patients presented with 24 bone metastases. On a patient level, the sensitivity and
specificity of MRI and PET were not significantly different. On a lesion level, the sensitivity of MRI
was significantly better compared to PET, and the specificity did not differ significantly. In conclusion,
axial MRI is an interesting screening tool for the detection of bone metastases because of its low
probability of false negative results. However, F-18 choline PET is a valuable addition as it can
overrule false positive MRI results and detect non-axial metastases.
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1. Introduction
A proportion of patients diagnosed with a rising prostate-specific antigen (PSA) following
treatment of prostate cancer with curative intent will develop a clinical recurrence during their
disease course. Some patients will do so in limited volume, for which metastasis-directed therapy
is an investigational approach [1]. However, traditional imaging studies, such as bone scan and
computed tomography, lack sufficient sensitivity to detect low volume metastatic disease at low
PSA levels [2]. Consequently, these imaging modalities are not recommended to detect metastases
in asymptomatic patients until the PSA rises above 10 ng/mL or high PSA kinetics are detected.
The role of functional imaging modalities such as Choline positron emission tomography/computed
tomography (PET/CT) has shown promising results to detect low volume metastases at low PSA
levels. The European Association of Urology (EAU) suggest referring patients for C-11 or F-18 choline
PET/CT in case the PSA rises >1 ng/mL if the result is expected to impact patient management [3].
In case of patients with limited metastatic disease, metastasis-directed therapy (MDT) by means
of surgery or external beam radiotherapy, is currently being investigated as a novel therapeutic
strategy [1,4]. In Belgium, the Surveillance or metastasis-directed Therapy for OligoMetastatic
Prostate cancer recurrence (STOMP) trial—a randomized trial comparing surveillance with metastasis
directed therapy MDT—is being performed with all eligible patients being screened with F-18 choline
PET/CT [5,6]. At the time of study initiation (2012), there was a lack of prospective data concerning the
sensitivity and specificity of F-18 choline PET/CT for the detection of bone metastases. Previous studies
have indicated that whole body magnetic resonance imaging (MRI) or axial skeleton MRI outperforms
bone scintigraphy for the detection of bone metastases in both the primary as the recurrent setting [7].
Consequently, patients potentially eligible for the STOMP trial were screened with both axial skeleton
MRI and F-18 choline PET/CT in order to establish their diagnostic accuracy for bone metastases.
2. Materials and Methods
We recruited 86 consecutive patients with a biochemical relapse [3] following local prostate cancer
treatment and testosterone levels >50 ng/dL at time of inclusion. The study was approved by our local
Ethics Committee (EC 2012/308) and patients signed informed consent.
PET/CT was performed 45 min following injection of 3–4 MBq/kg F-18 methyl Choline.
Patients were scanned from the base of skull to the proximal thighs. All PET/CT scans were co-reported
by two senior staff members of nuclear medicine and radiology (Bieke Lambert, Louke Delrue).
Double reading was performed by experienced nuclear medicine specialists (Paolo Castellucci,
Carlos Artigas, Kathia De Man). MRI included the entire spine with 3 mm sagittal short T1 inversion
recovery (STIR) and T1-weighted images, and pelvis with 5 mm coronal T1-weighted and fat
saturated proton-density and T2-weighted images. All scans were read in twofold by experienced
musculoskeletal radiologists (Wouter Huysse, Frédéric Lecouvet, Marie-Laurence Denis). In case of
conflicting interpretation of the scans, a third reader (VL) was appointed as adjudicator. Readers were
initially blinded from other scans, patient information and biological results. Panel reviews of initial
and follow-up imaging findings, with all available baseline and follow-up clinical and biologic data,
were used as the best valuable comparator (BVC) to define the true metastatic status [8]. A lesion-based
and patient-based analysis was conducted. We excluded patients in whom the interval between both
imaging studies exceeded 6 weeks. We also excluded patients who received systemic treatment or
without follow-up imaging making a formal evaluation of the metastatic status impossible. Therefore,
22 patients out of 86 recruited patients were excluded for the current analysis. Patient characteristics
can be found in the Table S1. The sensitivity and specificity of these approaches were compared using
the McNemar test, with p < 0.05 considered statistically significant.
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3. Results
In 15 out of 64 patients, 24 bone metastases were detected. Seven patients had a single lesion,
four patients presented with two lesions and three lesions were found in two patients. Two additional
patients suffered proven diffuse (>5 lesions) involvement, which could not be numerically correctly
accounted for in the lesion based analysis and were therefore considered as a single positive reading.
The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of
MRI and PET on both patient and lesion level are depicted in Table 1. On a patient level, the sensitivity
and specificity were not significantly different between MRI and PET (p = 0.5 and 0.5, respectively).
On a lesion level, the sensitivity of MRI (Figure 1) was significantly better compared to PET (p = 0.031).
The specificity was not significantly different between MRI and PET (p = 0.125).
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tomography (PET/CT) image (left) and (b) 5 mm coronal T1-weighted magnetic resonance (MR) image
of the sacro-iliac joints. In this patient three suspected bone metastases were reported on the PET and
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posteriorly in th right iliac bone (open arrow). O MRI, however, multiple T1-hypo-intense nodules
(small arrows) can be observed indicative of diffuse m tastatic dise se warranting ystemic reatment.
If CT observations had been considered in combination with PET, only a single patient would
have been incorrectly categorized as negative for bone metastases (sensitivity 93%, 95% CI: 0.66–0.99).
Regarding the l sion-based lev l, the combination with CT correctly assig ed 21/24 lesions, resulting
in a sensitivity of 88% (95% CI 0.67–0.97). However, since two patients with diffuse bone involvement
were heavily underestimated on both PET and CT, hich we annot num rically account for,
the calculated s nsitivities for F18 choline PET/CT are probably overrated.
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Table 1. Imaging results for predicting bone metastases on best value comparator.
Patient-Based Analysis
BVC for bone metastases
Image modality Scan result Negative (n = 49)No.
Positive (n = 15)
No.
Total (n = 64)




(95% CI) NPV % (95% CI)
Ax MRI
Negative 47 0 47
100 (75–100) 96 (84–99) 88 (62–98) 100 (91–100)
Positive 2 15 17
F-18 Choline PET
Negative 49 2 51 87 (58–98) 100 (91–100) 100 (72–100) 96 (85–99)
Positive 0 13 13 p = 0.5 p = 0.5
Lesion-based analysis
Image modality Scan result Negative (n = 55)No.
Positive (n = 24)
No.
Total (n = 79)




(95% CI) NPV % (95% CI)
Ax MRI
Negative 51 0 51
100 (83–100) 93 (82–98) 86 (66–95) 100 (91–100)
Positive 4 24 28
F-18 Choline PET
Negative 55 6 61 75 (53–89) 100 (91–100) 100 (78–100) 90 (79–96)
Positive 0 18 18 p = 0.031 p = 0.125
BVC = best value comparator, PPV = positive predictive value, NPV = negative predictive value, CI = confidence interval, Ax MRI = axial skeleton magnetic resonance imaging,
PET/CT = positron emission tomography/computed tomography.
Diagnostics 2017, 7, 56 5 of 6
4. Discussion
We addressed axial MRI versus F-18 choline PET/CT on a patient level as well as in a per-lesion
assessment. Non-castrated patients with a biochemical relapse following radical treatment of their
prostate cancer represent a heterogeneous population. Various research groups reported that patients
with low volume disease have a different tumor biology and prognosis compared to patients presenting
with high volume disease (“polymetastic disease”, >3 lesions) [6,9–11]. In the ongoing STOMP trial,
we recruit patients with low volume disease recurrence (up to three metastatic lesions, so-called
“oligometastatic disease”). They are offered metastasis directed treatment, e.g., surgery or external
beam radiotherapy. In our analysis, PET/CT with F-18 choline underestimated the polymetastatic
nature of the disease in two patients.
However, most patients do not suffer relapse disease limited to the axial skeleton [6]. In a large
prospective cohort (208 patients) from the Ghent University Hospital, three out of four patients with
a biochemical relapse following radical treatment for prostate cancer were categorized as low volume
disease, and in only 18% it concerned bone-only disease. The majority of patients presented with
lymph node involvement or a combination of nodal and skeletal metastasis. Therefore, the whole body
approach obtained by PET/CT is considered complementary to the axial MRI.
The advantages of both imaging modalities are available in hybrid PET/MRI scanners showing
promising data for relapsed prostate cancer [12], with an improved detection rate for bone metastasis
due to the MR component and a better evaluation of lymph nodes due to the use of PET. The recent
introduction of gallium-68 PSMA (prostate specific membrane antigen) as a PET tracer might further
improve results.
Recently, gallium-68 labeled prostate specific membrane antigen (Ga-68 PSMA) was introduced
as a PET/CT-tracer for restaging low volume prostate cancer. The yield of positive scans, in particular
at very low PSA levels, was proven to be higher for Ga-68 PSMA than obtained with radiolabeled
choline [13,14]. Non-controlled studies comparing Choline and PSMA also suggest a higher yield
for bone metastasis using PSMA [15]. However, validation by means of pathology or clinical
follow-up is still awaited in order to determine the sensitivity and specificity of Ga-68 PSMA in
this patient population.
5. Conclusions
In conclusion, both axial MRI and F-18 choline PET are valuable screening tools for the detection
of bone metastasis in prostate cancer. MRI outperformed choline PET/CT in terms of sensitivity in
a lesion-based analysis. However, the high specificity of choline PET/CT proved useful to overrule
false positive MRI results. Moreover, choline PET/CT allows for the detection of non-axial bone
metastases and metastatic lymph nodes.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/2075-4418/07/4/56/s1.
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